German Wireless Telecom Stock News

Evotec (XTRA:EVT) is still in the red, with losses having accelerated by 51.9% per year over the past five years and profit margins showing no sign of improvement. Despite this recent track record, the outlook is much brighter. Analysts see earnings growing at an impressive 74.86% per year, with profitability expected within the next three years and revenue set to climb 9% annually, outpacing the broader German market. These strong growth forecasts and a Price-To-Sales Ratio of just 1.4x...

Deutsche Lufthansa (XTRA:LHA) shares are in focus after Germany’s pilot union postponed planned industrial action, which has eased worries about potential disruptions. This move brings some breathing room for the airline and its investors. See our latest analysis for Deutsche Lufthansa. This pause in labor tensions comes shortly after Lufthansa’s quarterly report, which showed steadier long-term progress even as this quarter’s net income dipped compared to last year. The airline’s share price...

ZEAL Network (XTRA:TIMA) reported annual earnings growth of 6.68% and revenue growth of 8.3%, outperforming the German market’s 6.1% revenue expansion forecast. Net profit margins stand at 20.8%, down from 30.7% a year earlier. This highlights recent pressures despite a five-year stretch of 42.2% annualized earnings growth and persistent high-quality results. Investors are weighing this mix of sustained top-line progress, sliding margins, and flagged concerns around dividend sustainability as...

Dr. Ing. h.c. F. Porsche (XTRA:P911) has seen its stock move modestly in recent trading, with gains over the past month but still lagging compared to the previous year. Investors may be weighing long-term fundamentals as auto industry sentiment shifts. See our latest analysis for Dr. Ing. h.c. F. Porsche. Even with a recent bounce in the share price, Dr. Ing. h.c. F. Porsche’s momentum looks mixed, with a 1-day gain of 2.82% but a year-to-date share price return of -21.13% and a one-year...

adidas AG recently announced its third quarter 2025 results, reporting sales of €6.63 billion and net income of €461 million, both up from the previous year, alongside improved basic and diluted earnings per share. For the first nine months of 2025, the company's net income rose to €1.26 billion from €803 million, signaling increased profitability over the comparable period. We'll explore how these rising profits in the latest results may impact adidas' investment narrative and future...

In late October 2025, HelloFresh SE reconfirmed its guidance for fiscal year 2025, maintaining its previous outlook for a 6% to 8% constant currency revenue decline despite substantial business and reputational challenges. The company is facing a complex mix of core demand erosion, management risk factors, and multiple regulatory and ethical investigations, which collectively raise questions about its operational stability and leadership credibility. We’ll explore how ongoing scandals and...

As the European markets navigate a complex landscape of steady interest rates and mixed performances across major indices, investors are keenly observing opportunities that may arise from these fluctuations. In this context, identifying promising stocks often involves looking beyond immediate market trends to uncover companies with strong fundamentals and potential for growth amidst economic shifts.

Key Insights Using the 2 Stage Free Cash Flow to Equity, PNE fair value estimate is €16.86 PNE's €10.32 share price...

With a price-to-earnings (or "P/E") ratio of 2.3x TMM Real Estate Development Plc ( FRA:TR61 ) may be sending very...

Bayer (XTRA:BAYN) shares have seen some movement lately, which has investors and traders alike weighing the company’s recent performance against its longer-term outlook. The current environment invites a closer look at valuation and fundamentals. See our latest analysis for Bayer. Bayer’s share price has delivered a strong year-to-date return of 36.3 percent. However, momentum has cooled in recent weeks, with the past month’s share price down nearly 7 percent. Despite recent fluctuations,...

Evonik Industries (XTRA:EVK) posted a mixed set of results for investors, as EPS was pressured by a one-off €242 million loss over the past 12 months, dragging net profit margins down to 0.7% from 1.5% last year. Earnings have declined at an average annual rate of 32.4% over the past five years, but projections are turning heads. The company now expects earnings to grow 35.7% annually, which is significantly higher than the German market's 16.9% yearly growth forecast. While EVK's revenue...

As European markets experience mixed performances, with the STOXX Europe 600 Index recently pulling back slightly after reaching new highs, investors are closely watching for signals from the European Central Bank amid stable inflation rates. In this environment, dividend stocks can offer a measure of stability and income potential, making them an attractive option for those looking to navigate uncertain market conditions.

While Wacker Neuson SE ( ETR:WAC ) might not have the largest market cap around , it saw significant share price...

Wondering if Fresenius SE KGaA is truly a bargain or just riding the wave? You're not alone. The stock's value is a hot topic for investors eyeing healthcare giants. After soaring 43.5% year-to-date, with a 41.7% gain over the last year, it's clear things are moving. However, the past week has seen a 5.0% pullback, adding a dose of short-term volatility to the mix. Recent headlines have revolved around Fresenius advancing its strategic transformation, including portfolio streamlining and a...

Wondering if Deutsche Bank's incredible stock gains still leave room for value? You are not alone. We are about to decode what the numbers reveal. After climbing 1.8% in the last week, 5.9% over the past month, and an eye-watering 88.2% year-to-date, the stock has grabbed plenty of attention as momentum builds. The surge has been driven by upbeat industry sentiment and regulatory changes favoring European banks. Investor optimism around large financial institutions has also risen in the wake...

Elmos Semiconductor (XTRA:ELG) posted earnings growth of 21.5% over the last year, outpacing its current net profit margin of 22.2% compared to 17.2% in the previous period. Shares recently traded at €90.4, above an estimated fair value of €78.5 according to a discounted cash flow model. The stock’s Price-to-Earnings ratio of 12.5x stands well below peer and industry averages. With revenue expected to grow at 9.1% annually and margins expanding, the latest results underscore a compelling mix...

Nemetschek (XTRA:NEM) delivered earnings growth of 19.5% over the last year, handily outpacing its 5-year average of 11.5% per year. Net profit margin stands at 17.6%, a touch below last year’s 18.5%, with earnings expected to continue rising faster than the German market at 18.4% per year ahead. With solid growth forecasts and no flagged risks, investors will be weighing the strong growth outlook, high-quality earnings, and fair value discount against a premium Price-To-Earnings Ratio that...

Fresenius Medical Care (XTRA:FME) expects earnings to grow at 17.43% per year, backed by revenue projected to expand 4.1% annually. The company’s net profit margin has edged up to 3.7% from 3.4% a year ago. Earnings have also reversed a five-year decline of 17% per year to grow 9% over the past year. With shares trading at €41.76 and a price-to-earnings ratio of 16.8x, which is well below both peers and the European healthcare sector average, these numbers signal renewed momentum and...

Nordex (XTRA:NDX1) continued its remarkable earnings improvement, with profitability rising at an annual rate of 20.3% over the past five years and a dramatic jump of 384.7% in the latest year. Net profit margins climbed to 1.5%, up from 0.3% a year earlier. Revenue is forecast to grow 7.1% annually, topping the 6.1% pace of the wider German market. With earnings projected to increase 33.7% per year going forward, the company stands out for both ongoing growth and a strong margin turnaround...

Innoscripta (XTRA:1INN) continues its strong run with net profit margins climbing to 40.4%, up from 36.6% last year, and a substantial 82.2% earnings growth over the past year. This performance is well ahead of its already impressive five-year average of 44% per year. Looking forward, analysts expect both revenue and earnings to rise at rapid clips of 24.7% and 27.2% per year, respectively, outpacing the broader German market. Investors will likely view this momentum, paired with a share...

Schaeffler (XTRA:SHA0) currently faces rising losses, with net losses having grown 28.8% per year over the last five years and no reported improvement in net profit margin over the past twelve months. However, the company’s revenue is forecast to grow 3.6% per year, which trails the German market’s pace of 6.1%. Expectations are for a striking turnaround, with earnings projected to grow 135.4% annually and a return to profitability within three years. As investors weigh risks around financial...

Ever looked at Commerzbank and wondered if its surging share price means it's still a bargain, or if you've missed the boat? You're in the right place to find out what its real value might be. The stock has taken off this year, up a massive 109.3% year-to-date and delivering an impressive 101.3% gain over the last 12 months. This performance has caught the attention of both growth and value investors. Recent headlines have highlighted renewed momentum in Germany’s financial sector...

Wondering if Bayerische Motoren Werke is a smart buy right now? You are not alone, and there is a lot to unpack when it comes to figuring out whether the stock offers genuine value. The stock’s performance has been a mix of short-term volatility and longer-term growth, with a 16.7% gain over the past year and a 2.8% climb so far in 2024, despite recent dips in the last month. Recent headlines have focused on BMW’s ongoing investments in electric vehicles and strategic global partnerships,...

Wondering if Siemens Healthineers is trading at a great price or if you are chasing the story too late? You are not alone. Let's dig into what the current market is saying. The stock has nudged up 0.8% over the past week and managed a steady 3.5% gain for the year, signaling renewed interest and possibly shifting risk perceptions. Recent news around advancements in medical imaging technology and key partnerships have been grabbing headlines, giving investors more to weigh as the company...